Physician profile
Summer Slininger
NPI 1679248504
$6,535.35
in general payments reported to CMS, 2019-2025
24 companies · $2,479 in 2025
The $2,479 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $765 · 2024: $3,292 · 2025: $2,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,535.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.22 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,126.63 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $737.52 | 2023-2025 | Caplyta |
| Lundbeck LLC | $366.47 | 2023-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $323.61 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $307.56 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $296.46 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $285.37 | 2023-2025 | Auvelity |
| Bausch Health US, LLC | $265.43 | 2023-2025 | Wellbutrin, Aplenzin |
| Neos Therapeutics, Lp | $209.92 | 2023-2025 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $194.51 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $182.48 | 2024-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $141.01 | 2023-2025 | Ingrezza |
| Corium, LLC | $114.11 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $69.53 | 2025 | Austedo Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $64.43 | 2023 | Dyanavel Xr |
| Tms Neurohealth Centers INC. | $62.28 | 2025 | Tms Neurohealth Centers INC. |
| Collegium Pharmaceutical, INC. | $53.12 | 2025 | Jornay Pm |
| Alkermes, INC. | $51.39 | 2023-2024 | Lybalvi, Aristada |
| Almatica Pharma LLC | $46.71 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $36.69 | 2023 | Xelstrym |
| Biogen, INC. | $21.32 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $20.30 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Slininger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.